Protagonist Therapeutics, Inc. (PTGX) Balance Sheet
As of 2026-06-30 (10-Q), Protagonist Therapeutics, Inc. (PTGX) reported total assets of $885.5M, total liabilities of $44.0M and shareholders' equity of $841.5M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $420.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PTGXProtagonist Therapeutics, Inc.Follow PTGX — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 135.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 21.1 | 106.0 | 82.2 | 33.0 | 117.4 | 123.7 | 125.7 | 186.7 | 97.2 | 128.4 | 420.1 | |
| Short-term investments | 56.5 | 38.0 | 46.6 | 100.0 | 188.5 | 203.2 | 111.6 | 154.9 | 321.7 | 439.0 | 362.5 | |
| Current assets | 83.2 | 150.9 | 137.5 | 145.3 | 315.6 | 340.7 | 243.1 | 355.6 | 591.6 | 577.6 | 807.1 | |
| Total assets | 94.0 | 163.7 | 139.5 | 154.9 | 324.5 | 347.7 | 247.9 | 358.0 | 744.7 | 668.2 | 885.5 | |
| Current liabilities | 6.4 | 42.6 | 26.2 | 35.4 | 40.2 | 44.0 | 31.2 | 21.3 | 47.4 | 45.4 | 37.2 | |
| Long-term debt | — | — | — | 9.8 | — | — | — | — | — | — | — | |
| Total liabilities | 6.4 | 43.1 | 27.0 | 75.0 | 44.9 | 47.7 | 32.3 | 21.3 | 69.4 | 53.5 | 44.0 | |
| Shareholders' equity | 87.6 | 120.6 | 112.5 | 80.0 | 279.6 | 300.0 | 215.6 | 336.7 | 675.3 | 614.7 | 841.5 |
USD millions · SEC XBRL
Protagonist Therapeutics, Inc. — questions
- How much cash does Protagonist Therapeutics, Inc. have?
- $420.1M in cash and cash equivalents as of 2026-06-30.
- What are Protagonist Therapeutics, Inc.'s total assets?
- $885.5M as of 2026-06-30.
- What is Protagonist Therapeutics, Inc.'s shareholders' equity?
- $841.5M as of 2026-06-30.
Every figure on this page comes from Protagonist Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.